MindMaze Therapeutics Holding SA MMTX

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that Dr. John Krakauer has joined the Company as a strategic advisor to support its next phase of growth in the United States.

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today provided updates on two previously announced initiatives supporting its strategic priorities in neurology: the completion of its organizational simplification initiative, and the implementation of its CHF 8.0 million strategic equity financing with Neuro.io Group SA (Neuro.io). Together, these initiatives further support the execution of the Company'

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable, precision neurotherapeutics, today announced that its technology is being used in a University of Pittsburgh study evaluating a combination approach to post-stroke arm recovery, pairing cervical epidural spinal cord stimulation (SCS) with the Company's precision neurotherapeutics. The University of Pittsburgh is now enrolling participants.

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced that the SwissNeuroRehab consortium has enrolled the first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study. In parallel, MindMaze Therapeutics has launched the REACT-AVC study at Hospices Civils de Lyon, focused on early outpatient and home-based stroke rehabilitation. This progress marks a pivotal milestone in the

MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced the results of its Annual General Meeting held earlier today.

GENEVA, CH / ACCESS Newswire / June 3, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today published the invitation to its 2026 Annual General Meeting ...

GENEVA, CH / ACCESS Newswire / June 2, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced the sale of the U.S. and Canadian rights to ...

GENEVA, CH / ACCESS Newswire / May 26, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics, today announced it has entered into a definitive agreement for ...

Vibra to Support Expansion of MindMaze Therapeutics' Neurorehabilitation Platform across Leading U.S. Health Systems GENEVA, SWITZERLAND AND MECHANICSBURG, PENNSYLVANIA / ACCESS Newswire / May 12, 2026 / MindMaze Therapeutics, a pioneer in advanced ...

Former Rune Labs and Glooko executive to lead MindMaze's next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care. GENEVA, SWITZERLAND / ACCESS Newswire / March 12, 2026 / MindMaze Therapeutics ...

GENEVA, CH / ACCESS Newswire / March 3, 2026 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics, or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today ...